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Aims Long-QT syndromes (LQTS) are mostly autosomal-dominant congenital disorders associated with a 1:1000 mutation
frequency, cardiac arrest, and sudden death. We sought to use cardiomyocytes derived from human-induced pluripo-
tency stem cells (hiPSCs) as an in vitromodel to develop and evaluate gene-based therapeutics for the treatment of LQTS.
Methods and
results
We produced LQTS-type 2 (LQT2) hiPSC cardiomyocytes carrying a KCNH2 c.G1681A mutation in a IKr ion-channel
pore, which caused impaired glycosylation and channel transport to cell surface. Allele-specific RNA interference
(RNAi) directed towards the mutated KCNH2 mRNA caused knockdown, while leaving the wild-type mRNA un-
affected. Electrophysiological analysis of patient-derived LQT2 hiPSC cardiomyocytes treated with mutation-specific
siRNAs showed normalized action potential durations (APDs) and K+ currents with the concurrent rescue of spon-
taneous and drug-induced arrhythmias (presented as early-afterdepolarizations).
Conclusions These findings provide in vitro evidence that allele-specific RNAi can rescue diseased phenotype in LQTS cardiomyo-
cytes. This is a potentially novel route for the treatment of many autosomal-dominant-negative disorders, including
those of the heart.
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Introduction
With the prevalence of 1:1000 individuals, inherited long-QT syn-
dromes (LQTS) are life-threatening disorders caused by abnormal
ventricular repolarization1 due to mutations in at least 13 genes
encoding cardiac ion-channel proteins.2 Patients with LQTS have
an increased risk of Torsades de Pointes (polymorphic ventricular
tachycardia), which can present as palpitations, syncope (fainting),
seizures, cardiac arrest, and sudden death.3 Of LQTS cases, 45%
are classified as LQTS-type 2 (LQT2), caused by mutations in
KCNH2 (also known as hERG), which encodes the a-subunit of a
tetrameric complex forming part of the rapid-acting inward recti-
fying potassium (Ikr) channel.
4 Over 500 hERG mutations are iden-
tified, which primarily show autosomal-dominant-negative
inheritance. Function of the wild-type (WT) protein is compro-
mised by mutated (Mut) protein, thus resulting in reduced Ikr func-
tion due to altered gating properties5 or impaired protein
trafficking sometimes linked to glycosylation defects, inappropriate
protein maturation and proteasomal degradation.6
Treatments for LQT2 include the administration of b-
adrenoceptor antagonists (b-blockers) or, in patients at a high
risk of sudden death, surgery for implantation of pacemakers,
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cardioverter defibrillators, and left cardiac sympathetic denerv-
ation.7 However, limitations in current therapies have prompted
investigations to further understand disease pathology, and
develop and safety screen novel pharmacological treatments.
Such research has been based on the use of in vitro transgenic or
immortalized cell lines (e.g. HEK293) and animal models (e.g.
guinea-pig myocytes, arterially perfused canine and rabbit left ven-
tricular wedge preparations), as well as in vivo toxicity studies in
monkeys, dogs, and mouse.8 However, a particular limitation of
the mouse is the reliance on different ion channels relative to
human (mouse, Ito, IK,slow1, IK,slow2, ISS; human, IKs, IKr) during the
cardiac action potential.9 Lack of predictive translation of such
models towards human behaviour4 has led to the development
of a multitude of functionally relevant, humanized in vitro models
for LQTS via use of induced pluripotency technologies.10 These
have successfully shown that patient’s clinical profiles and response
to pharmacology are faithfully reflected in vitro, including for
LQT2.11
Here, we sought to explore the disease-causing biophysical
mechanisms of LQT2-associated c.G1681A (p.Ala561Thr) mis-
sense mutation in KCNH2, with view to developing novel patient-
specific treatments. By coupling induced pluripotency technologies
to RNA interference (RNAi)-based therapy, we demonstrated
that allele-specific mRNA knockdown of Mut hERG is feasible in
human cardiomyocytes. This treatment rescued electrophysio-
logical characteristics of LQT2 human-induced pluripotency stem
cell (hiPSC)-derived cardiomyocytes, as evidenced by normalized
action potential durations and increased K+ current. Moreover,
treated cells did not develop early-afterdepolarizations (EADs) in
response to adrenergic stimulation or potassium blockage, drug
treatments that induce arrhythmias in LQT2 patients. These data
suggest that allele-specific RNAi warrants further in vivo investiga-
tion as a treatment modality for LQTS and other autosomal-
dominant-negative genetic diseases.
Methods
Details on hiPSCs, including isolation of patient tissue, generation,
culture, and characterization, as well as generation of high titre lenti-
virus are previously published.11,12 In vitro differentiation to cardiomyo-
cytes was via embryoid body (EB) formation, based on previous
publication.13
Electrophysiology analysis
For multi-electrode array (MEA) analysis, beating clusters between
Days 12 and 16 of differentiation were mounted on MEAs (Multi-
channel Systems), and extracellular field potential measurements per-
formed according to previous guidelines.14 For whole-cell recordings
of action potentials by patch-clamp, cardiomyocyte clusters were dis-
aggregated to single cells using published method and buffers,15 and
recordings were obtained in the current mode using an ECP-10 amp-
lifier (HEKA). During recordings cells were maintained at 378C in
normal Tyrode’s buffer, while patch pipettes and buffer were as previ-
ously described.11 Data were recorded using the Pulse software
(HEKA) and analysed using Clampfit v9.0 (Molecular Devices). Cardi-
omyocyte subtypes were determined as previously described.11
Briefly, APD90/50 values ,1.4 designated ventricular cells, 1.4–1.7
designated pacemaker cells, and .1.7 designated atrial cells.
Transduction and transfection with
KCNH2 constructs
Following sterilization of plasmid DNA (Supplementary material
online Methods), at 658C for 10 min, cells were transfected using
LipofectamineTM 2000 (Invitrogen) as per previous publications,16 or
transduced with lentivirus at MOI 10, generated as previously
described.17 For cardiomyocyte transduction, lentivirus was pre-
incubated with Polybrenew (Sigma-Aldrich) for 5 min before addition
to the cells, as published before.18 This was performed to increase
transduction efficiency since Polybrenew is known to neutralize
charge repulsion between viral particles and sialic acid on the cell
surface.19
siRNA transfection
siRNAs against WT or Mut hERG were designed based on optimum
discrimination parameters,20 and ordered (Invitrogen) with dTdT
3′ modification. LacZ-siRNA was included as a non-targeting control
(F: 5′-CUACACAAAUCAGCGAUUU, R: 5′-AAAUCGCUGAUUU
GUGUAG) and had fluorescein 5′ modification to allow transfection
efficiency quantification. For transgene knockdown, 20 mM double-
stranded siRNAs (5 mL) mixed with ExGen500 lipid (7 mL; Fermentas;
2:2 siRNA:lipid ratio) were used to transfect 10 000 fibroblasts. For en-
dogenous gene knockdown, 2.5 mL siRNA were mixed with 3.5 mL
ExGen500 lipid (1:1 siRNA:lipid ratio) and used to transfect 10 000
cardiomyocytes. Transfections were performed in OptiMEM (Invitro-
gen) for 4 h, according to lipid manufacturer’s instructions.
shRNA gateway cloning
shRNA oligos (Invitrogen) were annealed by heating to 948C for 4 min,
then 708C for 10 min, and cooled-down at room temperature for 1 h.
Double-stranded shRNAs were ligated, for 30 min, into linearized
pENTR/U6 expression vector according to manufacturer’s instructions
(BLOCK-iTTM U6 RNAi Entry Vector Kit; Invitrogen). For transient
over-expression, vectors were transfected as for pSIN-EF2 vectors
above. For stable over-expression, shRNA/U6 cassette was recombined
into pLenti X2 Neo DEST vector (Addgene) using Gatewayw LR Clona-
sew II Enzyme (Invitrogen) according to manufacturer’s instructions,
lentivirus generated as above, and cells infected at MOI 25.
Allele-specific gene expression
RT–PCR performed as previously described11 with 2 mL cDNA, and
the addition of 1.5 mM MgCl2 (QIAGEN) for WT cDNA or 2.5 mM
MgCl2 for Mut cDNA. Common forward primer was used for both
cDNAs (F: 5′-ACTTCAAGGGCTGGTTCCTC). Reverse primer for
WT cDNA was R: 5′-ATGCAGGCTAGCCAGTGCTC and for Mut
allele R: 5′-ATGCAGGCTAGCCAGTGCTT. PCR conditions were
958C for 15 min then 37 cycles (958C, 1 min; 598C, 30 s; 728C,
1 min) with the final extension at 728C for 5 min. SYBRw Green Real-
time PCR performed with 2× JumpStartTM Taq ReadyMixTM (10 mL;
Sigma-Aldrich), reference dye 0.02 mL, 2.5 mM MgCl2, and same
primers as above (2 mL). PCR conditions were 508C for 20 s, 958C
for 10 min then 37 cycles (958C, 15 s; 598C, 1 min) with data collec-
tion after the 598C, 1 min step. Amplification was followed by continu-
ous melt-curve analysis.
Statistical analysis
Data presentation and significance scoring were as previously
described.11 Within-group data were reported as mean values of ex-
perimental replicates+ standard deviation. Wild-type and Mut hERG
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monomer incorporation into tetramers before and after Mut mRNA
knockdown was statistically modelled using binomial distribution.
Choice of the statistical model was based on the apparent random as-
sembly of WT and Mut hERG alleles into tetramers and their statistical
independence. Therefore, the probability of a tetramer containing
WT: Mut alleles at a ratio of k:(n2 k) for k ¼ 0,1, . . . ,n were calcu-
lated using: prob(k:n2 k) ¼ C(n, k) pk (12 p)n2k, where n ¼ 4,
C(n, k) is the binomial coefficient, and p is the fraction of WT mono-
mers in the total hERG population. The formula for prob(k:n2 k) can
be understood as follows: for a tetramer to contain WT:Mut alleles
at a ratio of k:(4 2 k), we need k monomers of WT giving a probability
of pk, and (42 k) monomers of Mut giving a probability of (12 p)42 k.
However, the successful choice of the WT monomer can occur any-
where among the n ¼ 4 trials. Namely, there are C(n, k) different
ways of distributing k successes in a sequence of n trials thus giving
the resulting formula.
Results
hERG c.G1681A mutation causes
electrophysiological abnormalities
in Long-QT syndromes-type 2
cardiomyocytes
Human-induced pluripotency stem cells were generated from a
patient with LQT2-related mutation c.G1681A in KCNH2, and
from genetically matched controls including the patient’s father
(genetically normal) and mother (asymptomatic carrier of same
mutation, not under b-blocker treatment). Full 12-lead electrocar-
diograms (ECGs) for all family members have been previously pub-
lished.11 Differentiation of hiPSCs produced beating clusters within
8–16 days,13 which contained cardiomyocytes as evidenced by
characteristic cardiac muscle striations upon immunostaining
(Figure 1A). Electrophysiological analysis by whole-cell patch-clamp
of individual human pluripotent stem cell (hPSC) cardiomyocytes
showed cultures contained ventricular (32%), atrial (41%), and
pacemaker-like (27%) cell subtypes (Figure 1B). Multi-electrode
array analysis showed that compared with cardiomyocytes gener-
ated from HUES7 human embryonic stem cells (hESCs; 845+
78 ms, n ¼ 11), and the patient’s father (LQT2-PAT; 836+
78 ms, n ¼ 6) and mother (LQT2-MAT; 795+174 ms, n ¼ 6),
LQT2 cardiomyocytes had significantly prolonged field potential
duration (FPD: 1084+ 1.65, P ¼ 0.01, n ¼ 10; Figure 1C), which
correlates to the patient’s ECG indications.11 The same was true
when LQT2 ventricular (APD: 929+ 167 ms, P ¼ 0.01, n ¼ 13),
atrial (APD: 1126+260 ms; P ¼ 0.004, n ¼ 14), and pacemaker-
like (APD: 882+222 ms, P ¼ 0.02, n ¼ 9) cardiomyocytes were
compared with controls (combined data from hESCs,
LQT2-PAT, and LQT2-MAT) by patch-clamp electrophysiology
(Figure 1D). Treatment with E4031 (1 mM), a selective IKr channel
blocker, caused APD prolongation in control cardiomyocytes
(378+ 229.0 ms, n ¼ 6), and arrhythmogenesis appearing as
EADs only in LQT2 cardiomyocytes (occurrence rate 1:2,
n ¼ 6), indicating increased sensitivity to IKr blockage (Figure 1E).
All analysis was performed in two independent hiPSC-lines
per patient to avoid side-effects form line-to-line variation.
Deep-sequencing of the LQT2-genome also confirmed absence
of additional known disease-associated mutations in cardiac
arrhythmia-related genes (Table SI), therefore leaving differences
between mother-daughter phenotype-to-genotype correlations
unanswered.
hERG c.G1681A mutation causes
dominant-negative trafficking
defect in cardiomyocytes
To explore disease-causing biophysical mechanism of KCNH2
c.G1681A mutation, we interrogated predicted hERG folding
using SWISS-MODEL tools, which showed amino-acid substitution
of alanine to threonine did not cause structural protein change
(Figure 2A). Further studies were conducted using transgenic
disease systems in fibroblasts and HEK293 cells (Supplementary
material online, Figure S2), where western blot analysis confirmed
the presence of glycosylation/maturation defect in Mut hERG
(Figure 2C), correlating to previous publications.21 Fluorescence
staining detected distinct hERG localization patterns, which for
the WT overlapped to pan-cadherin and fibroblast surface
markers (Figure 2Di– ii, Supplementary material online, Figure
S3B), but was perinuclear for Mut hERG (Figure 2Ei– ii). This also
confirmed that glycosylation defect leads to impaired protein traf-
ficking.22 Next, clones over-expressing WT hERG-GFP were gen-
erated and showed an indistinguishable localization pattern when
compared with non-tagged WT hERG clones, confirming the
GFP tag did not compromise hERG localization (Supplementary
material online, Figure S2E). When WT hERG-GFP was transfected
into Mut transgenic lines, the GFP signal lacked surface localization
(Figure 2F i and ii), indicating a dominant-negative phenotype likely
due to the formation of non-functional WT/Mut tetramers with
defective hERG surface transport. Finally, lentiviral transduction
with paramagnetic bead-bound virus, previously proven to
enhance viral uptake,12 showed that transgene over-expression
can be detected in hPSC cardiomyocytes (Supplementary material
online, Figure S4B) at 5–6 days post-transduction (PTD). This also
enabled detection of over-expressed hERG in single cardiomyo-
cytes demonstrating that in functionally relevant human cells,
WT hERG is co-localized with surface marker pan-cadherin
(Figure 2Diii) while Mut formed perinuclear aggregates
(Figure 2Eiii). Defective trafficking was also seen in cardiomyocytes
co-infected with WT and Mut lentivirus (Figure 2Fiii), confirming
dominant-negative effect.
Testing potential drug therapies against
hERG c.G1681A dominant-negative
trafficking defect
Having validated c.G1681A mutation results in a hERG-dominant-
negative trafficking defect, we wished to investigate novel, effective,
and patient-specific treatments for this LQT2 mutation. Studies in
immortalized cell-lines have suggested thaspigargin, fexofenadine,
or E4031 enhance hERG cell-surface transport.22,23 Therefore,
we exposed Mut fibroblasts to above drugs (10 nM to 10 mM),
and stained with anti-hERG antibody. Fluorescence microscopy
did not show improved hERG trafficking with thaspigargin or fex-
ofenadine at any concentrations tested (data not shown). Although
E4031 facilitated surface localization at 1 mM (Supplementary ma-
terial online, Figure S5A), our data showed this concentration also
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induced arrhythmogenesis in LQT2 cardiomyocytes (Figure 1E).
E4031 experiments were, thus, not carried forward. To restore
impaired K+ currents, LQT2 cardiomyocytes were next treated
with potassium-channel openers; nicorandil (20 mM) and
PD-118057 (3 mM), which enabled shortening of the otherwise
prolonged APD by 293.8+84.8 and 213.2+26.5 ms, respective-
ly, and by 627.4+100.2 ms when used in combination (Supple-
mentary material online, Figure S5B). Combined treatment
rendered APD in LQT2 cardiomyocytes similar to controls
(653+100 and 613+122 ms, respectively). However, the admin-
istration of potassium-channel openers and isoprenaline, to mimic
stress simulation, triggered abnormalities (Supplementary material
online, Figure S5B), perhaps due to excessive APD shortening re-
quiring very fast repolarization that cells lacking functional hERG
could not cope with. This suggests that LQT2 patients potentially
undertaking this treatment could suffer arrhythmias during activ-
ities inducing sympathetic stimulation (e.g. exercise, stress).
Testing potential gene therapies against
hERG c.G1681A dominant-negative
trafficking defect
Current routes for gene therapy include targeted gene correction,
transgene over-expression and RNAi for either knockdown or
exon-skipping in Mut genes. Gene targeting has been achieved in
vitro using hiPSC disease models,10 and in animal in vivo models
using zinc-finger nucleases,24 but not yet in humans. Also, gene tar-
geting requires proliferating cells in the S-phase of the cell-cycle,25
so it is of limited use for the treatment of predominantly quiescent
heart cells, while the structurally intact state of patients’ hearts (i.e.
absence of scar tissue or lesions) impedes transplantation of
cardiac progenitors following targeted gene correction.
Figure 2Diii shows WT hERG over-expression with surface localiza-
tion can be achieved in cardiomyocytes via lentiviral transduction.
As a therapeutic route, transgene over-expression could be uti-
lized to shift the ratio of WT to Mut alleles, increasing the
number of functional hERG tetramers capable of surface localiza-
tion. However, while lentiviral WT-hERG over-expression was
achieved, onset was delayed (5–6 days PTD) and infection effi-
ciency was low (52%). Also, since transgene over-expression
levels can be uncontrolled and reach cardiotoxic levels,26 this
therapeutic route could face clinical challenges.
We reasoned a more controlled way to regulate and improve
formation and trafficking of functional hERG tetramers would be
to use allele-specific mRNA knockdown. We designed RNAi con-
structs based on mismatch position guidelines previously pub-
lished,20 with sequences tethered around KCNH2 c.G1681A
mutation. Four siRNAs were designed against either WT or Mut
KCNH2 (Figure 3A, Supplementary material online, Figure S6A), to
determine the robustness of allelic knockdown, and converted
to shRNA sequences cloned (Supplementary material online,
Figure S6B) into pDEST/U6 Gateway lentiviral vectors
Figure 1 Long-QT syndrome-type 2 hiPSC cardiomyocytes can recapitulate the disease phenotype in vitro. (A) Long-QT syndrome-type 2
cardiomyocytes showed characteristic cardiac muscle striations with cardiac troponin-I staining, and (B) formed ventricular (n ¼ 11), atrial
(n ¼ 14), and pacemaker-like (n ¼ 9) myocytes. (C) Long-QT syndrome-type 2 cardiomyocytes had prolonged field potential duration
(n ¼ 10) and (D) action potential duration compared with controls, which included cardiomyocytes derived from human embryonic stem
cells, the patient’s father (long-QT syndrome-type 2-PAT) and mother (long-QT syndrome-type 2-MAT). (E) E4031 (1 mM) treatment
caused prolongation in action potential duration of control cardiomyocytes (n ¼ 6), depicting the presence of functional hERG channels,
and caused arrhythmias only in long-QT syndrome-type 2 cardiomyocytes (n ¼ 6).
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(Supplementary material online, Figure S6C). Vector delivery into
transgenic WT/Mut hERG fibroblasts was used to evaluate the spe-
cificity and efficiency of knockdown 72 h PTD, to allow time for
VSV-G pseudo-typed vector initial integration into the host
genome (can take at least 12–48 h).27 WT-G10 shRNA (75.9%
knockdown) and Mut-A13-shRNA (70.5% knockdown) were
most effective in reducing allele-specific transcripts without affect-
ing the other allele (Figure 3B, Supplementary material online, Figure
S6D). Flow cytometry analysis indicated hERG protein knockdown
approached mRNA knockdown levels on Days 6–9 PTD (65.2 and
71.8%, respectively; Figure 3C). Delay in protein compared with
mRNA knockdown was attributed to hERG protein turn-over,
known to be 11–16 h.28,29 WT protein was unaffected by
A13-shRNA, when compared with a LacZ-shRNA control (Supple-
mentary material online, Figure S6E). Results suggested that allele-
specific mRNA knockdown warranted further investigation in
LQT2 cardiomyocytes.
Allele-specific RNAi can knockdown
mutated hERG in long-QT
syndrome-type 2 cardiomyocytes
Having validated allele-specific knockdown at the gene and protein
levels, we synthesized siRNAs corresponding to A13 sequences.
siRNA transfection efficiencies were optimized using fluorescently
tagged oligos in transgenic fibroblast lines (98.8–99.8%, Supple-
mentary material online, Figure S7) and LQT2 hiPSC cardiomyo-
cytes (84%, Figure 4B, Supplementary material online, Figure S8).
In disaggregated single cardiomyocytes or small beating clusters
of five to six cells, siRNA transfection was not significantly cyto-
toxic as it did not compromise spontaneous contraction or struc-
tural integrity when the 1:1 siRNA:lipid ratio was used (see section
‘Methods’, Figure 4B, Supplementary material online, Figure S8B).
siRNA treatment at the 2:2 ratio (or higher), enabled 100% car-
diomyocyte transfection but was detrimental to structural integrity
as shown by cardiac troponin-I staining (Supplementary material
online, Figure S8A) and was not used in knockdown experiments.
Allele-specific mRNA knockdown by A13-siRNA was confirmed
in fibroblast transgenic lines (Figure 4Ai), and repeated transfection
with siRNA every 48 h for 6 days sustained knockdown of Mut
KCNH2 (Figure 4Aii). In LQT2 cardiomyocytes, A13-siRNA
enabled 61.8% knockdown of endogenous Mut KCNH2 mRNA
compared with controls (untreated and treated with LacZ-siRNA),
without affecting WT mRNA (Figure 4C). This is the first report
documenting allele-specific knockdown of an endogenous mRNA
in heart cells, or indeed hiPSCs and their differentiated derivatives.
Based on observations that gene knockdown levels correlate to
protein knockdown (Figure 3C), statistical modelling fitted to the
Figure 2 KCNH2 mutation c.G1681A causes a hERG-dominant-negative trafficking defect. (A) SWISS-MODEL structural analysis of amino
acid residues: 408 to 665 showing no effect in hERG monomer folding due to c.G1681A mutation. (B) Site-directed mutagenesis in wild-type
hERG1a cDNA generated mutant form for over-expression studies. (C) Western blot showing the absence of fully glycosylated mature hERG in
fibroblast lines over-expressing mutant transgene. Fluorescence staining showing over-expression of (D) wild-type and (E) Mut hERG in
(i) HEK293 cells, (ii) fibroblasts, and (iii) hESC cardiomyocytes, depicting impaired surface localization of Mut hERG (red). Cell surface outlined
with pan-cadherin staining (lilac; also see Supplementary material online, Figure S3). (F) Impaired surface localization of GFP-tagged wild-type
hERG (green) in (i) HEK293 and (ii) fibroblast cell lines co-expressing Mut hERG, depicting the dominant-negative phenotype of the mutant
form. (F) (iii) Fluorescence staining showing simultaneous over-expression of wild-type and Mut hERG in hESC-derived cardiomyocytes
causes lack of surface localization. Scale-bar: 15 mm.
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binomial distribution was used to predict the likelihood of func-
tional hERG tetramer formation following Mut hERG knockdown.
Results indicated that this level knockdown of endogenous Mut
hERG could enhance the likelihood of functional protein tetramer
formation from 0.0625 (6.25%) to 0.2757 (27.57%; Figure 4D),
meaning a potential 4.5-fold increase in IKr current. This could
shift the phenotype of LQT2 cardiomyocytes towards that of an
asymptomatic mutation carrier or normal individual. Indeed, simul-
taneous transduction of cardiomyocytes with hERG WT, Mut, and
A13-shRNA lentiviral constructs co-incubated onto paramagnetic
beads (can bind hundreds of virions/bead), indicated considerable
improvement in surface localization for hERG (Figure 4E).
This demonstrated specific knockdown of Mut transgene could al-
leviate dominant-negative phenotype and allow corrected WT
localization.
Electrophysiological properties of
siRNA-treated long-QT syndrome-type 2
cardiomyocytes
We next investigated the effect of siRNA knockdown on LQT2
hiPSC-cardiomyocyte function. Patch-clamp electrophysiology
showed the otherwise prolonged APD of ventricular, atrial, and
pacemaker-like myocytes was shortened by 279+ 148 ms (P ¼
0.35, n ¼ 8), 438+142 ms (P ¼ 0.01, n ¼ 15), and 212+ 66 ms
(P ¼ 0.03, n ¼ 17), respectively, following A13 treatment when
compared with control LQT2 cardiomyocytes (Figure 5A and B).
APD50 and APD9011 values were also shortened (% decrease in
Figure 5A). Spontaneous arrhythmias observed in control LQT2
myocytes (occurrence rate 1:3, n ¼ 21) were never detected in
A13-treated cells (Figure 5C), indicating rescue of LQT2
arrhythmogenic phenotype. Voltage-clamp recordings demon-
strated increased K+ current in A13-treated LQT2 cardiomyocytes
(n ¼ 5), suggesting APD shortening could be due to improved
repolarization ability from A13 treatment.
A13-treated LQT2-myocytes did not develop isoprenaline-
induced arrhythmias (n ¼ 10; Figure 6B), suggesting patients
under siRNA therapy could have increased tolerance to exercise
or stress. This was in contrast to control LQT2 cardiomyocytes
(n ¼ 10, Figure 6A), and cardiomyocytes under combined Nicoran-
dil and PD-118057 treatment which had enabled comparable APD
decrease to siRNA treatment (Supplementary material online,
Figure S5B). In addition, siRNA-treated myocytes showed no
arrhythmias with E4031 treatment (n ¼ 5, Figure 6B), which indi-
cates that patients potentially undertaking this therapy could be
less susceptible to drug-induced cardiac episodes when adminis-
tered drugs with cardio-toxic QT-elongation side-effects.30 In
summary, although focusing on one specific LQT2 mutation, the
results presented here are evidence that allele-specific RNAi can
rescue LQTS phenotype, in a humanized functionally relevant
in vitro disease model.
Discussion
Biophysical disease mechanisms of LQT2-associated mutation
c.G1681A were analysed in this paper and exploited to validate a
novel therapeutic treatment in patient-specific hiPSC cardiomyo-
cytes. Treatment was based on RNAi technologies to specifically
knockdown Mut hERG alleles, while leaving the WT unaffected,
and maintaining contractibility and structural integrity in cardio-
myocytes. The quiescent state of human cardiomyocytes poses a
major obstacle for other in vivo cardiac therapies, such as a targeted
Figure 3 Design and validation of hERG allele-specific mRNA knockdown. (A) Rational design of siRNAs against mutated (1681A) KCNH2
mRNA. siRNA nomenclature based on distinguishing nucleotide between wild-type and mutant alleles, and its position from the siRNA 5′-end
(e.g. A13). (B) (i) RT and (ii) real-time PCR showed shRNAs over-expressed through pDEST/U6 lentiviral vector enabled knockdown of Mut
KCNH2 mRNA in fibroblasts carrying lentiviral over-expression of both wild-type (G) and Mut (A) mRNAs. A13-shRNA enabled the highest
level knockdown (70.5%), without affecting wild-type mRNA. (C) Flow cytometry showed A13-shRNA also enabled 65–71.8% Knockdown of
Mut hERG protein from Day 6 post-transduction. All mRNA and protein knockdown experiments were repeated twice with n ¼ 2 per treat-
ment. For further details, also see ‘Methods’ section.
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gene correction by zinc-finger nucleases where cells need to enter
the S-phase of the cell-cycle.25 In contrast, we show that human
cardiomyocytes can readily uptake and express siRNA molecules.
In LQT2 cardiomyocytes, Mut mRNA was knocked-down by
61.8%, increasing likelihood of functional hERG tetramer formation
by 4.5-fold. Consequently, APD in siRNA-treated LQT2 cardio-
myocytes was shortened, K+ currents increased, and spontaneous
as well as isoprenaline and E4031-induced arrhythmias abolished.
These are significant findings since they demonstrate that adrener-
gic stimulation and potassium current blockage, which often evoke
arrhythmic episodes in LQT2 patients,30,31 are prevented by RNAi
treatment.
In vivo specificity and efficacy of allele-specific RNAi in animal
models of LQTS, delivery methods, safety, dosage, and timing
issues would need to be addressed before this therapy for LQTS
was transferred to the clinic. Other RNAi-based animal and clinical
trials for the treatment of disorders such as cancer, age-related
macular degeneration, respiratory syncytical virus pulmonary infec-
tions, and Duchenne muscular dystrophy use targeted systemic
nanoparticle delivery for siRNA administration to patients,32 deliv-
ery via intravitreal and i.v. injection of naked siRNA33,34 or admin-
istration in the form of nasal sprays.35 In vivo siRNA delivery to
human cardiomyocytes has not been reported to date, but
mouse studies show rapid and efficient siRNA biodistribution in
Figure 4 siRNA-mediated knockdown of mutated hERG in long-QT syndrome-type 2 cardiomyocytes. (A) In fibroblasts carrying lentiviral
over-expression of both wild-type and mutant alleles. (i) A13-siRNAs against mutant KCNH2 enabled allele-specific mRNA knockdown for
up to 48 h. (ii) Repeat-transfection with siRNAs every 48 h (red arrows) sustained knockdown up to Day 6 post-initial transfection. All
mRNA knockdown experiments repeated twice with n ¼ 2 per treatment. (B) long-QT syndrome-type 2 cardiomyocytes were successfully
transfected with fluorescein-tagged siRNAs (green, n ¼ 42), while maintaining (i) morphology, spontaneous contraction and (ii) structural in-
tegrity, as shown by staining with cardiac troponin-I (cardiac troponin-I ¼ red; blue ¼ DAPI nuclear stain). (C) A13-siRNA-mediated 61.8%
knockdown of mutant KCNH2 in long-QT syndrome-type 2 cardiomyocytes. (D) Statistical analysis of the likelihood for functional hERG tetra-
mer formation following mutant knockdown showed that the formation of functional hERG tetramers can increase by 4.5-fold, from 6 to 27%.
(E) Fluorescence staining showing co-expression of (i) wild-type hERG, Mut hERG, and LacZ-shRNA (n ¼ 10), or (ii) wild-type hERG, Mut
hERG, and A13-shRNA (n ¼ 10) in hESC cardiomyocytes, depicting impaired hERG (red) surface localization in (i) and considerably improved
localization in (ii). Cell surface outlined with pan-cadherin staining (lilac). Scale-bar: 15 mm.
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Figure 5 Electrophysiology analysis in siRNA-treated long-QT syndrome-type 2 cardiomyocytes. (A) Patch-clamp electrophysiology showing
A13-siRNA treatment decreased action potential duration, APD50 and APD90, in long-QT syndrome-type 2 cardiomyocytes (ventricular:
n ¼ 8, atrial: n ¼ 15, pacemaker: n ¼ 17). (B) Overlays of representative traces from control and A13-treated long-QT syndrome-type 2 ven-
tricular, atrial, and pacemaker cardiomyocytes. (C) Averaged and raw data of spontaneous arrhythmias, in the form of early-afterdepolarizations,
observed only in control long-QT syndrome-type 2 cardiomyocytes (n ¼ 21). (D) Voltage-clamp showing increased K+ currents with A13
treatment (n ¼ 5).
Figure 6 Isoprenaline and E4031 drug treatment in siRNA-treated long-QT syndrome-type 2 cardiomyocytes. (A) (i) Averaged and (ii) raw
data of isoprenaline-induced arrhythmias in the form of early-afterdepolarizations observed only in control long-QT syndrome-type 2 cardio-
myocytes (n ¼ 10). (B). (i) Isoprenaline (100 nM, n ¼ 10) or (ii) E4031 (1 mM, n ¼ 5) treatment in A13-treated long-QT syndrome-type 2 car-
diomyocytes did not cause early-afterdepolarizations, depicting rescue of long-QT syndrome-type 2-phenotype by RNAi-based therapy.
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several internal organs, including the heart, via i.v. injection.36
Injected macroscopic biomaterial scaffolds or conjugation to pep-
tides could also allow siRNA delivery specifically to human
hearts.37 Tissue-specific delivery would alleviate potential off-
target effects of siRNAs in non-cardiac cells.
Allele-specific mRNA knockdown is a largely unexploited novel
concept with wide applications the future treatment of human dis-
eases. It has previously been tested against triplet repeat expan-
sions in the Huntingtin gene with knockdown validation in HeLa
cells,38 and SNP mutation in the procollagen type III gene with val-
idation in skin fibroblasts form a rare (prevalence 1:100 000)
Ehlers-Danlos syndrome patient.39 Study of allele-specific mRNA
knockdown has never been shown for common conditions and
where isolation of affected human tissue is challenging, such as in
cardiac disorders. Here, hiPSC reprogramming technologies
enabled generation of patient-specific cardiomyocytes, faithfully re-
capitulating disease pathologies in vitro, compared with genetically
matched controls, where benefits of allele-specific knockdown
were assessed in functional human cells. This would pave the
way towards further in vivo testing in animal models of LQTS and
ultimately clinical trials that could personalize clinical treatment
for not only LQTS mutations (prevalence 1:1000), but also
other congenital cardiovascular and non-cardiovascular disorders
caused by autosomal-dominant-negative mutations.
Supplementary material
Supplementary material is available at European Heart Journal
online.
Acknowledgements
The authors would like to thank Kati Kemppainen and Dr Kid
To¨rnquist (A˚bo Akademi University, Finland) as well as Jennifer
Abbruzzese and Prof Michael Sanguinetti (The University of
Utah, USA) for wild-type hERG1a cDNA constructs, Dr Paul Bur-
ridge (Stanford University School of Medicine, USA) for advice on
high-efficiency differentiation of hESCs to cardiomyocytes, and
Joa˜o Bigares (Cardiff University, UK) for advice on cardiomyocyte
electrophysiology analysis.
Funding
This work was supported by the British Heart Foundation (BHF), the
Medical Research Council (MRC), and the Biotechnology and Biologic-
al Sciences Research Council (BBSRC).
Conflict of interest: none declared.
References
1. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet 2008;372:
750–763.
2. Bokil NJ, Baisden JM, Radford DJ, Summers KM. Molecular genetics of long QT
syndrome. Mol Genet Metab 2011;101:1–8.
3. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable
inherited cardiomyopathies/channelopathies in clinical practice. Circulation 2011;
123:1021–1037.
4. Lehnart SE, Ackerman MJ, Benson DW Jr, Brugada R, Clancy CE, Donahue JK,
George AL Jr, Grant AO, Groft SC, January CT, Lathrop DA, Lederer WJ,
Makielski JC, Mohler PJ, Moss A, Nerbonne JM, Olson TM, Przywara DA,
Towbin JA, Wang LH, Marks AR. Inherited arrhythmias: a National Heart, Lung,
and Blood Institute and Office of Rare Diseases workshop consensus report
about the diagnosis, phenotyping, molecular mechanisms, and therapeutic
approaches for primary cardiomyopathies of gene mutations affecting ion
channel function. Circulation 2007;116:2325–2345.
5. Yang HT, Sun CF, Cui CC, Xue XL, Zhang AF, Li HB, Wang DQ, Shu J.
HERG-F463L potassium channels linked to long QT syndrome reduce I(Kr)
current by a trafficking-deficient mechanism. Clin Exp Pharmacol Physiol 2009;36:
822–827.
6. Mihic A, Chauhan VS, Gao X, Oudit GY, Tsushima RG. Trafficking defect and pro-
teasomal degradation contribute to the phenotype of a novel KCNH2 long QT
syndrome mutation. PLoS One 2011;6:e18273.
7. Schimpf R, Veltmann C, Wolpert C, Borggrefe M. Arrhythmogenic hereditary syn-
dromes: Brugada Syndrome, long QT syndrome, short QT syndrome and CPVT.
Minerva Cardioangiol 2010;58:623–636.
8. Medeiros-Domingo A, Iturralde-Torres P, Ackerman MJ. Clinical and genetic
characteristics of long QT syndrome. Rev Esp Cardiol 2007;60:739–752.
9. Davis RP, van den Berg CW, Casini S, Braam SR, Mummery CL. Pluripotent stem
cell models of cardiac disease and their implication for drug discovery and devel-
opment. Trends Mol Med 2011;17:475–484.
10. Matsa E, Denning C. In vitro uses of human pluripotent stem cell-derived cardio-
myocytes. J Cardiovasc Trans Res 2012;5:581–592.
11. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C. Drug
evaluation in cardiomyocytes derived from human induced pluripotent stem cells
carrying a long QT syndrome type 2 mutation. Eur Heart J 2011;32:952–962.
12. Dick E, Matsa E, Bispham J, Reza M, Guglieri M, Staniforth A, Watson S, Kumari R,
Lochmuller H, Young L, Darling D, Denning C. Two new protocols to enhance
the production and isolation of human induced pluripotent stem cell lines. Stem
Cell Res 2011;6:158–167.
13. Burridge PW, Thompson S, Millrod MA, Weinberg S, Yuan X, Peters A,
Mahairaki V, Koliatsos VE, Tung L, Zambidis ET. A universal system for highly ef-
ficient cardiac differentiation of human induced pluripotent stem cells that elim-
inates interline variability. PLoS One 2011;6:e18293.
14. Mahlstedt MM, Anderson D, Sharp JS, McGilvray R, Barbadillo Munoz MD,
Buttery LD, Alexander MR, Rose FR, Denning C. Maintenance of pluripotency
in human embryonic stem cells cultured on a synthetic substrate in conditioned
medium. Biotechnol Bioeng 2010;105:130–140.
15. Moore JC, van Laake LW, Braam SR, Xue T, Tsang SY, Ward D, Passier R,
Tertoolen LL, Li RA, Mummery CL. Human embryonic stem cells: genetic ma-
nipulation on the way to cardiac cell therapies. Reprod Toxicol 2005;20:377–391.
16. Braam SR, Denning C, Matsa E, Young LE, Passier R, Mummery CL. Feeder-free
culture of human embryonic stem cells in conditioned medium for efficient
genetic modification. Nat Protoc 2008;3:1435–1443.
17. Dick E, Matsa E, Young LE, Darling D, Denning C. Faster generation of hiPSCs by
coupling high-titer lentivirus and column-based positive selection. Nat Protoc
2011;6:701–714.
18. Li S, Kimura E, Fall BM, Reyes M, Angello JC, Welikson R, Hauschka SD,
Chamberlain JS. Stable transduction of myogenic cells with lentiviral vectors
expressing a minidystrophin. Gene Ther 2005;12:1099–1108.
19. Davis HE, Rosinski M, Morgan JR, Yarmush ML. Charged polymers modulate
retrovirus transduction via membrane charge neutralization and virus aggregation.
Biophys J 2004;86:1234–1242.
20. Huang H, Qiao R, Zhao D, Zhang T, Li Y, Yi F, Lai F, Hong J, Ding X, Yang Z,
Zhang L, Du Q, Liang Z. Profiling of mismatch discrimination in RNAi enabled ra-
tional design of allele-specific siRNAs. Nucleic Acids Res 2009;37:7560–7569.
21. Chugh SS, Senashova O, Watts A, Tran PT, Zhou Z, Gong Q, Titus JL, Hayflick SJ.
Postmortem molecular screening in unexplained sudden death. J Am Coll Cardiol
2004;43:1625–1629.
22. Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, Gong Q,
Zhou Z, Ackerman MJ, January CT. Most LQT2 mutations reduce Kv11.1
(hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation 2006;
113:365–373.
23. Rajamani S, Anderson CL, Anson BD, January CT. Pharmacological rescue of
human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene
rescue without block. Circulation 2002;105:2830–2835.
24. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, Malani N, Anguela XM,
Sharma R, Ivanciu L, Murphy SL, Finn JD, Khazi FR, Zhou S, Paschon DE, Rebar EJ,
Bushman FD, Gregory PD, Holmes MC, High KA. In vivo genome editing restores
haemostasis in a mouse model of haemophilia. Nature 2011;475:217–221.
25. Carroll D. Genome Engineering With Zinc-Finger Nucleases. Genetics 2011;188:
773–782.
26. Salama G, London B. Mouse models of long QT syndrome. J Physiol 2007;
578(Pt 1):43–53.
27. Van Maele B, De Rijck J, De Clercq E, Debyser Z. Impact of the central polypurine
tract on the kinetics of human immunodeficiency virus type 1 vector transduction.
J Virol 2003;77:4685–4694.
Allele-specific RNAi rescues LQTS phenotype Page 9 of 10
 at U
niversity of N
ottingham
 on M
arch 25, 2014
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
28. Soltan MK, Ghonaim HM, El Sadek M, Kull MA, El-aziz LA, Blagbrough IS. Design
and synthesis of N4,N9-disubstituted spermines for non-viral siRNA delivery—
structure-activity relationship studies of siFection efficiency versus toxicity.
Pharm Res 2009;26:286–295.
29. Walker VE, Atanasiu R, Lam H, Shrier A. Co-chaperone FKBP38 promotes HERG
trafficking. J Biol Chem 2007;282:23509–23516.
30. Vieweg WV, Wood MA. Tricyclic antidepressants, QT interval prolongation, and
torsade de pointes. Psychosomatics 2004;45:371–377.
31. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C,
Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH,
Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW,
Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E,
Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation
in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.
Circulation 2001;103:89–95.
32. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y,
Heidel JD, Ribas A. Evidence of RNAi in humans from systemically administered
siRNA via targeted nanoparticles. Nature 2010;464:1067–1070.
33. Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, Do DV, Reisen G,
Lockridge JA, Short B, Guerciolini R, Nguyen QD. RNAi-based treatment for
neovascular age-related macular degeneration by Sirna-027. Am J Ophthalmol
2010;150:33–39 e2.
34. Cirak S, Feng L, Anthony K, Arechavala-Gomeza V, Torelli S, Sewry C, Morgan JE,
Muntoni F. Restoration of the dystrophin-associated glycoprotein complex after
exon skipping therapy in Duchenne muscular dystrophy. Mol Ther 2012;20:
462–467.
35. Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv Drug
Deliv Rev 2012;64:1–15.
36. Arnold AS, Tang YL, Qian K, Shen L, Valencia V, Phillips MI, Zhang YC. Specific
beta1-adrenergic receptor silencing with small interfering RNA lowers high
blood pressure and improves cardiac function in myocardial ischemia.
J Hypertens 2007;25:197–205.
37. Krebs MD, Alsberg E. Localized, Targeted, and Sustained siRNA Delivery. Chemistry,
2011;17:3054–3062.
38. Takahashi M, Watanabe S, Murata M, Furuya H, Kanazawa I, Wada K, Hohjoh H.
Tailor-made RNAi knockdown against triplet repeat disease-causing alleles. Proc
Natl Acad Sci U S A 2010;107:21731–21736.
39. Muller GA, Hansen U, Xu Z, Griswold B, Talan MI, McDonnell NB, Briest W.
Allele-specific siRNA knockdown as a personalized treatment strategy for vascu-
lar Ehlers-Danlos syndrome in human fibroblasts. FASEB J 2012;26:668–677.
E. Matsa et al.Page 10 of 10
 at U
niversity of N
ottingham
 on M
arch 25, 2014
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
